

AtCor secures \$1.0 million new pharmaceutical trial contract

AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced that it has signed a significant new contract to supply SphygmoCor® systems and clinical trial support services. The new deal is with a major international pharmaceutical company that is a new client for AtCor.

The clinical trial is in the treatment of heart failure and will be conducted across several European sites. It is a phase II trial which, if successful, is expected to open a larger opportunity for AtCor. It will run for 18-24 months and the majority of revenue will be recognised in FY2019.

The CEO of AtCor Medical, Craig Cooper said: "This contract is further validation of our core technology in large pharmaceutical trials for the treatment of heart failure and related disorders and is a testament to our team's efforts in expanding our revenue base with large multinational clients".

Duncan Ross, Executive Director of AtCor Medical said: "We are delighted to have secured this contract with a major new client. There is increasing interest in utilising SphygmoCor in heart failure trials and in the clinic. Heart failure is a high cost disease state where drug selection, dosing and patient monitoring are of critical importance. This is our second heart failure trial to commence in the past 6 months and discussions are underway for additional trials."

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen. In the US alone, approximately 5.7 million people have heart failure at a total economic cost of over US \$30 billion per annum¹.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of arterial stiffness, hypertension, target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, doctors' offices, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

¹ Centers for Disease Control and Prevention – Division for Heart Disease and Stroke Prevention

SphygmoCor® is a registered trademark of AtCor Medical Pty Ltd and its related parties.

For personal use only

For further information, please contact:
AtCor Medical

Duncan Ross –Executive Director
+1 (630) 228 8873

Peter Manley –CFO
+61 (2) 8815 8811

Media enquiries to:
Financial & Corporate Relations

Ashley Rambukwella
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

For personal use only